Eli Lilly & Co. (LLY) Tops Q4 EPS by 29c, Lifts Outlook
Tweet
Share
E-mail
Get Alerts LLY Hot Sheet
Price: $1,098.57 --0%
Revenue Growth %: +31.7%
Financial Fact:
Acquired in-process research and development: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Revenue Growth %: +31.7%
Financial Fact:
Acquired in-process research and development: 0
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Eli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $2.09, $0.29 better than the analyst estimate of $1.80. Revenue for the quarter came in at $7.3 billion versus the consensus estimate of $7.35 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2023 EPS of $8.35-$8.55, versus the consensus of $8.28. Eli Lilly & Co. sees FY2023 revenue of $30.3-30.8 billion, versus the consensus of $30.55 billion.
For earnings history and earnings-related data on Eli Lilly & Co. (LLY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ennis (EBF) Reports In-Line Q1 EPS
- Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
- International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
